High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer
Authors
Keywords
-
Journal
ACTA ONCOLOGICA
Volume 60, Issue 9, Pages 1210-1217
Publisher
Informa UK Limited
Online
2021-06-05
DOI
10.1080/0284186x.2021.1933585
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of PD-L1 expression in the tumor microenvironment
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer
- (2021) Niclas C. Blessin et al. Aging-US
- MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer
- (2020) Yi‐Lin Chen et al. CELL BIOLOGY INTERNATIONAL
- Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
- (2020) Niclas C. Blessin et al. CELLULAR ONCOLOGY
- The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
- (2020) Daniel R. Almquist et al. BIODRUGS
- Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
- (2020) Darleny Y. Lizardo et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer
- (2020) Sebastian Dwertmann Rico et al. Medical Molecular Morphology
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort
- (2019) Ann C. Eriksen et al. BMC CANCER
- PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1
- (2019) Hsiang-Ling Ho et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer
- (2019) Michael A. Morse et al. ONCOLOGIST
- Application of PD-1 Blockade in Cancer Immunotherapy
- (2019) Xiaomo Wu et al. Computational and Structural Biotechnology Journal
- BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts
- (2019) Daofu Feng et al. ONCOGENE
- Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer
- (2019) Yang Feng et al. Cancer Management and Research
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer
- (2019) Calik et al. Medicina-Lithuania
- Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
- (2019) Xianguang Bai et al. OncoTargets and Therapy
- Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression
- (2019) Jung-Soo Pyo et al. PATHOLOGY RESEARCH AND PRACTICE
- Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer
- (2018) TUMENJIN ENKHBAT et al. ANTICANCER RESEARCH
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
- (2018) Margarita Udall et al. Diagnostic Pathology
- CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer
- (2018) Soo Jung Lee et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments
- (2018) Anna Maria Valentini et al. Oncotarget
- Stromal PD-1 / PD-L1 expression predicts outcome in colon cancer patients
- (2018) Jacqueline Wyss et al. Clinical Colorectal Cancer
- Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability
- (2017) Shotaro Korehisa et al. INTERNATIONAL JOURNAL OF CANCER
- Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
- (2017) Huan Bin Wang et al. Journal of Digestive Diseases
- PD-L1 expression in HNPCC-associated colorectal cancer
- (2017) Naila Shiraliyeva et al. PATHOLOGY RESEARCH AND PRACTICE
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
- (2017) Seung Tae Kim et al. Oncotarget
- Tumour CD274 (PD-L1) expression and T cells in colorectal cancer
- (2016) Yohei Masugi et al. GUT
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- (2016) Matthew W Rosenbaum et al. MODERN PATHOLOGY
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Programming tools: Adventures with R
- (2014) Sylvia Tippmann NATURE
- B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells
- (2013) Sheng-Jia Shi et al. PLoS One
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started